In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emisphere Technologies Inc.

www.emisphere.com

Latest From Emisphere Technologies Inc.

Pipeline Watch: Xarelto, CVT-301 And Ameluz Phase III Readouts

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

Sinopharm/Oramed Deal Sets Up Huge China Market For Oral Insulin

Chinese pharmaceutical giant Sinopharm’s subsidiary has finalized a licensing agreement with Israeli firm Oramed for China rights to an oral insulin capsule, paving the way for further changes in the country’s huge diabetes market. Hefei meanwhile is pushing ahead with plans to become China’s high-end insulin production base, helped by several cross-border collaborations.

BioPharmaceutical China

Deals Shaping The Medical Industry, November 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October 2015.

BioPharmaceutical Medical Device

Deal Watch: Bristol Doubles Down On Five Prime, Roche Continues Diversifying

Roche buyout of California biotech Adheron will strengthen its pipeline in rheumatoid arthritis and fibrosis. Lilly keeps busy, expanding an immuno-oncology collaboration with China's Innovent and acquiring a Phase III intranasal hypoglycemia candidate from Locemia.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Emisphere Technologies Inc.
  • Senior Management
  • Alan L Rubino, Pres. & CEO
    Peter J Shaw, CMO
    Carlos DeLecea, Global Head, Bus. Dev.
    Carl V Sailer, VP, Sales & Mktg.
  • Contact Info
  • Emisphere Technologies Inc.
    Phone: (973) 532-8000
    4 Becker Farm Rd. Ste. 103
    Roseland, NJ 07068
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register